Abstract Disclosures
feasibility and efficacy of this approach.
Methods: Eligibility criteria were: radiological diagnosis of recurrent or progressive GBM, previously treated by surgical resection followed by 3D-CRT (total dose 59,4 Gy) plus based on cisplatin and fotemustine in 7 patients and on TMZ in 13 patients. Hematologic toxicity was mild, with a G3-4 (leucopenia) observed in 5% of patients; no treatment related death was observed. One out of 20 patients (5%) had a complete response, 1 patient (5%) experienced a partial response (PR), while 5 patients (25%) had a stable disease (SD) lasting at least 8 weeks (Clinical Benefit 35%). The median PFS and OS from relapse were 5 and 7 months, respectively; survival rate at 6 months was 58.7 % with an OS at 1 year of 26.7 %. No differences were observed between the two schedules of chemotherapy.
Conclusions: These data suggest that chemotherapy plus LD-FRT as second-line treatment is safe and well tolerated, encouraging the prosecution of the study.
